Is OMER stock a Buy, Sell, or Hold?

Based on our analysis, OMER is currently a HOLD with moderate confidence. 📊 HOLD: OMER shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of OMER stock?

Our analysis estimates the fair value range for OMER to be between $17.58 and $19.84. The current price is $16.86.

What is the analyst price target for OMER?

The average Wall Street analyst price target for OMER is $27.50. This implies a potential upside of 63.1% from current levels.

Omeros (OMER) Stock: Buy, Sell, or Hold?

OMER - Omeros Corporation

PHARMACEUTICAL PREPARATIONS

$16.86

0.60 (3.69%) ▲

5d: -10.27%

30d: -18.71%

90d: +72.22%

HOLD

MODERATE Confidence

Protect Your OMER Gains

Analysis Updated: Oct 22, 2026 12:00 AM ET

Earnings: Nov 12, 2026 19d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Oct 16, 2026 at $16.21 · last confirmed Oct 20, 2026

Strength: 6.9/10

Get Alerted When OMER Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: OMER shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$59.88

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$37.18

54.7% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: OMER is currently trading at $16.86, which is considered oversold relative to its 30-day fair value range of $17.58 to $19.84. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.7) compared to its historical average (60.1). Remarkably, the market is currently pricing in an annual earnings decline of 38.9% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, OMER is in a strong uptrend. Immediate support is located at $15.85, while resistance sits at $20.24. The stock is showing strong short-term momentum, up 3.7% recently.

Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $27.50 (+63.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $17.58 - $19.84

Company Quality Score 60/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 84.3%

Protect Your Profits

Holding OMER? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Mixed technical signals (55/100)
BULLISH: High volume confirmation
BULLISH: Strong upward momentum (+3.7%)
BULLISH: Trading 63.1% below Wall St target ($27.50)
NEUTRAL: Bottoming setup forming (55/100) — watch for confirmation
CAUTION: 5-day price weakness (-10.3%) - monitor closely

Trading Range Analysis

30-Day Trading Range $17.58 - $19.84

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $15.85

Resistance Level $20.24

Current Trend Strong Uptrend

Technical data as of Oct 22, 2026

Fundamental Context

Forward P/E (Next Year Est.) 13.71

Wall Street Target $27.50 (+63.1%)

Revenue Growth (YoY) 14.9%

Profit Margin 324.9%

Valuation Discount vs History -38.9% cheaper

PE vs Historical 13.7 vs 60.1 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -38.9% (market-implied from PE analysis)

1-Year Target $15.17 (-10%)

2-Year Target $13.66 (-19%)

3-Year Target $12.29 (-27%)

3-Yr Target (if PE normalizes) (PE: 14→60) $53.89 (+220%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 19.9, Growth: 78.3%) $82.44 (+389%)

Base: (SPY PE: 13.7, Growth: 78.3%) $56.90 (+238%)

Bear: (PE: 11.7, Growth: 78.3%) $48.37 (+187%)

📈 Valuation based on Current Earnings

Trailing PE: 13.55 | Current EPS (TTM): $1.20

Bull Case $18.33 (+9%)

Analyst growth 2.5%, PE expands to 14.9

Base Case $16.67 (-1%)

Market implied 2.5%, PE stable at 13.6

Bear Case $11.06 (-34%)

Severe decline -20.0%, PE contracts to 11.5

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 13.7 to 60.1

Stabilization Target: $73.92 (+338.5%)

PE Expansion Potential: +338.5%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 23, 2026 2:15 AM ET
Data refreshes hourly during market hours. Next update: 3:15 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is OMER showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for OMER.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
BMRN Biomarin Pharmaceutical …	STRONG BUY 28 analysts	$92	67 BUY
BBIO BridgeBio Pharma Inc	STRONG BUY 23 analysts	$108	58 HOLD
INCY Incyte Corporation	HOLD 28 analysts	$130	77 BUY
SRRK Scholar Rock Holding Corp	STRONG BUY 18 analysts	$70	71 BUY
AXSM Axsome Therapeutics Inc	STRONG BUY 22 analysts	$283	49 HOLD

BMRN Biomarin Pharmace…

67 BUY

BBIO BridgeBio Pharma …

58 HOLD

INCY Incyte Corporation

77 BUY

SRRK Scholar Rock Hold…

71 BUY

AXSM Axsome Therapeuti…

49 HOLD

Advanced OMER Option Strategies

Professional options setups generated by AI based on today's OMER price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for OMER

OMER Technical Chart OMER Price Prediction OMER Earnings Date OMER Investment Advisor OMER Fair Price Analyzer OMER Options Advisor OMER Options Chain OMER Options Analysis OMER Competitors

Compare OMER with Peers

OMER vs OCUL
Which one to buy?

OMER vs KPTI
Which one to buy?

OMER vs PTCT
Which one to buy?

OMER vs MGNX
Which one to buy?

OMER vs TGTX
Which one to buy?

JNJ vs OMER

OMER vs IMNM

OMER vs CVAC

OMER vs XERS
Winner: XERS

OMER vs STOK
Winner: OMER

OMER vs RCUS
Winner: RCUS

TTRX vs OMER

OMER vs SNDX
Winner: OMER

OMER vs ZYME

OMER vs NUVB
Winner: NUVB

Create New Comparison View All Competitors

Tradestie